These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 6289629

  • 21. Pseudoirreversible binding of opiates to opioid receptor subtypes in rat brain: a quantitative study.
    Xu H, Kim CH, Zhu YC, Weber RJ, Rice KC, Rothman RB.
    NIDA Res Monogr; 1990; 105():410-1. PubMed ID: 1652086
    [No Abstract] [Full Text] [Related]

  • 22. Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D-2-Nal(4)]endomorphin-2 (Antanal-2).
    Fichna J, do-Rego JC, Chung NN, Lemieux C, Schiller PW, Poels J, Broeck JV, Costentin J, Janecka A.
    J Med Chem; 2007 Feb 08; 50(3):512-20. PubMed ID: 17266203
    [Abstract] [Full Text] [Related]

  • 23. Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes.
    Lester PA, Traynor JR.
    Brain Res; 2006 Feb 16; 1073-1074():290-6. PubMed ID: 16443205
    [Abstract] [Full Text] [Related]

  • 24. Evaluation of new compounds for opioid activity.
    Woods J, Medzihradsky F, Smith C, Winger G, France C.
    NIDA Res Monogr; 1988 Feb 16; 90():421-67. PubMed ID: 2855859
    [No Abstract] [Full Text] [Related]

  • 25. Properties of the putative epsilon opioid receptor: identification in rat, guinea pig, cow, pig and chicken brain.
    Nock B, Giordano AL, Moore BW, Cicero TJ.
    J Pharmacol Exp Ther; 1993 Jan 16; 264(1):349-59. PubMed ID: 8380865
    [Abstract] [Full Text] [Related]

  • 26. From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH.
    Balboni G, Cocco MT, Salvadori S, Romagnoli R, Sasaki Y, Okada Y, Bryant SD, Jinsmaa Y, Lazarus LH.
    J Med Chem; 2005 Aug 25; 48(17):5608-11. PubMed ID: 16107162
    [Abstract] [Full Text] [Related]

  • 27. Selectivity profile of nor-binaltorphimine and ICI-197,067 in guinea pig brain.
    Magnan J, Tiberi M.
    Prog Clin Biol Res; 1990 Aug 25; 328():73-6. PubMed ID: 2154822
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Site-directed alkylation of multiple opioid receptors. I. Binding selectivity.
    James IF, Goldstein A.
    Mol Pharmacol; 1984 May 25; 25(3):337-42. PubMed ID: 6328259
    [Abstract] [Full Text] [Related]

  • 30. Opioid tolerance and dependence in light of the multiplicity of opioid receptors.
    Schulz R, Herz A.
    NIDA Res Monogr; 1984 May 25; 54():70-80. PubMed ID: 6099881
    [No Abstract] [Full Text] [Related]

  • 31. Side chain methyl substitution in the delta-opioid receptor antagonist TIPP has an important effect on the activity profile.
    Tourwé D, Mannekens E, Diem TN, Verheyden P, Jaspers H, Tóth G, Péter A, Kertész I, Török G, Chung NN, Schiller PW.
    J Med Chem; 1998 Dec 17; 41(26):5167-76. PubMed ID: 9857087
    [Abstract] [Full Text] [Related]

  • 32. Opioid mu, delta, and kappa receptor-induced activation of phospholipase C-beta 3 and inhibition of adenylyl cyclase is mediated by Gi2 and G(o) in smooth muscle.
    Murthy KS, Makhlouf GM.
    Mol Pharmacol; 1996 Oct 17; 50(4):870-7. PubMed ID: 8863832
    [Abstract] [Full Text] [Related]

  • 33. Progress in the characterization of the opioid receptor subtypes: peptides as probes. Future directions.
    Simon EJ.
    NIDA Res Monogr; 1986 Oct 17; 70():155-74. PubMed ID: 3020421
    [No Abstract] [Full Text] [Related]

  • 34. Synthesis and biological evaluation of 14-alkoxymorphinans. 22.(1) Influence of the 14-alkoxy group and the substitution in position 5 in 14-alkoxymorphinan-6-ones on in vitro and in vivo activities.
    Lattanzi R, Spetea M, Schüllner F, Rief SB, Krassnig R, Negri L, Schmidhammer H.
    J Med Chem; 2005 May 05; 48(9):3372-8. PubMed ID: 15857143
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Evaluation of new compounds for opioid activity: 1982 annual report.
    Woods JH, Katz JL, Medzihradsky F, Smith CB, Winger GD.
    NIDA Res Monogr; 1983 Apr 05; 43():457-511. PubMed ID: 6410277
    [No Abstract] [Full Text] [Related]

  • 37. The binding and analgesic properties of a sigma opiate, SKF 10,047.
    Pasternak GW, Carroll-Buatti M, Spiegel K.
    J Pharmacol Exp Ther; 1981 Oct 05; 219(1):192-8. PubMed ID: 6270299
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The proenkephalin A fragment peptide E is metabolized centrally to a novel peptide with opioid activity.
    Davis TP, Shook JE, Gillespie TJ, Culling-Berglund AJ, Papietro HM, Porreca F.
    Proc West Pharmacol Soc; 1987 Oct 05; 30():321-5. PubMed ID: 3628299
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.